MedTrace Logo

HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

NCT02908763 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-05-22

No results posted yet for this study

Summary

HBsAg Loss/Seroconversion is uncommon in Low replicative chronic HBV infection patients. The purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg loss/seroconversion therapy in Low replicative chronic HBV infection patients with Low Level HBsAg.

Conditions

Interventions

DRUG

peginterferon alfa

peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Nanchang University

    collaborator OTHER

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • First People's Hospital, Shunde China

    collaborator OTHER

  • Shenzhen Third People's Hospital

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Tang-Du Hospital

    collaborator OTHER

  • First Affiliated Hospital of Kunming Medical University

    collaborator OTHER

  • Yuebei People's Hospital

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02908763 on ClinicalTrials.gov